Soligenix Inc. (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302’s potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. The company is leveraging its experience with hypericin-based therapies to address a significant market opportunity, projected to reach $67 billion by 2030, while expanding its dermatology presence.
Psoriasis is a chronic autoimmune condition characterized by red, scaly patches on the skin, affecting approximately 125 million people worldwide. Current treatments range from topical corticosteroids to biologics, but many have limitations including side effects, cost, or limited efficacy. SGX302, a synthetic hypericin formulation, is designed to be activated by visible light, offering a targeted photodynamic therapy approach. This mechanism may provide a well-tolerated option for patients with mild-to-moderate psoriasis, a segment where treatment gaps persist.
The ongoing phase 2a trial is evaluating SGX302 in patients with mild-to-moderate psoriasis, with early data indicating a favorable safety profile and signs of biological activity. These results are consistent with prior phase 1/2 findings, which demonstrated the therapy's potential. Soligenix plans to use these data to guide larger studies and seek regulatory guidance, moving toward potential commercialization. The company has a history of developing hypericin-based therapies, including HyBryte (SGX301) for cutaneous T-cell lymphoma, which has completed phase 3 trials and is awaiting regulatory approvals.
Soligenix’s expansion into psoriasis represents a strategic move into a larger market. The global psoriasis treatment market is expected to grow significantly, driven by increasing prevalence and demand for safer, more effective therapies. If successful, SGX302 could capture a share of this market, offering a novel alternative to existing treatments. The company’s experience with regulatory pathways and commercialization for HyBryte may also streamline development for SGX302.
Investors can track the latest news and updates relating to SNGX in the company’s newsroom at https://ibn.fm/SNGX. For more information about Soligenix, visit the company’s website at www.Soligenix.com. The full article discussing these developments is available at https://ibn.fm/4WFZG.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing HyBryte (SGX301) as a photodynamic therapy for cutaneous T-cell lymphoma, and expanding synthetic hypericin (SGX302) into psoriasis. The company also has programs in innate defense regulators, including dusquetide (SGX942) for inflammatory diseases, and vaccines for ricin, filoviruses, and COVID-19 under its Public Health Solutions segment. These programs are supported by government grants and contracts from agencies such as NIAID, DTRA, and BARDA.
